Evidence map›Paper›PMID 36750912›Full record

ReviewStem cell research & therapy2023

Shining the light on mesenchymal stem cell-derived exosomes in breast cancer.

Ghaidaa Raheem Lateef Al-Awsi, Fahad Alsaikhan, Ria Margiana, Irfan Ahmad, Indrajit Patra, Mazin A A Najm, Ghulam Yasin, Iroda Rasulova, Ali Thaeer Hammid, Hamzah H Kzar and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 7 countries.

Ghaidaa Raheem Lateef Al-AwsiDepartment of Radiological Techniques, Al-Mustaqbal University College, Babylon, Iraq.
Fahad AlsaikhanCollege of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Kingdom of Saudi Arabia.
Ria MargianaDepartment of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. ria.margiana@ui.ac.id.
Irfan AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Indrajit PatraIndependent Researcher, Durgapur, West Bengal, India.
Mazin A A NajmPharmaceutical Chemistry Department, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq.
Ghulam YasinDepartment of Botany, Bahauddin Zakariya University, Multan, Pakistan.
Iroda RasulovaIndependent Researcher, "Kasmed" Private Medical Centre, Tashkent, Uzbekistan.
Ali Thaeer HammidComputer Engineering Techniques Department, Faculty of Information Technology, Imam Ja'afar Al-Sadiq University, Baghdad, Iraq.
Hamzah H KzarVeterinary Medicine College, Al-Qasim Green University, Al-Qasim, Iraq.
Moaed E Al-GazallyCollege of Medicine, University of Al-Ameed, Karbala, Iraq.
Homayoon SiahmansouriDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. siahmansouri.homa@gmail.com.
Bahauddin Zakariya University · PKImam Ja’afar Al-Sadiq UniversityKing Khalid University · SAMinistry of Higher Education and Scientific Research · IQNational Institute of Technology Durgapur · INPrince Sattam Bin Abdulaziz University · SATabriz University of Medical Sciences · IRTashkent Pediatric Medical Institute · UZThi Qar University · IQUniversity of Indonesia · IDUniversity of Karbala · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In women, breast cancer (BC) is the second most frequently diagnosed cancer and the leading cause of cancer death. Mesenchymal stem cells (MSCs) are a subgroup of heterogeneous non-hematopoietic fibroblast-like cells that have the ability to differentiate into multiple cell types. Recent studies stated that MSCs can migrate into the tumor sites and exert various effect on tumor growth and development. Multiple researches have demonstrated that MSCs can favor tumor growth, while other groups have indicated that MSCs inhibit tumor development. Emerging evidences showed exosomes (Exo) as a new mechanism of cell communication which are essential for the crosstalk between MSCs and BC cells. MSC-derived Exo (MSCs-Exo) could mimic the numerous effects on the proliferation, metastasis, and drug response through carrying a wide scale of molecules, such as proteins, lipids, messenger RNAs, and microRNAs to BC cells. Consequently, in the present literature, we summarized the biogenesis and cargo of Exo and reviewed the role of MSCs-Exo in development of BC.

Indexed as

Breast NeoplasmsExosomesMesenchymal Stem CellsMicroRNAsFemaleHumansMicroRNAsBreast cancerExosomeExtracellular vesiclesMesenchymal stem cellTumor

Identifiers

PMID36750912
PMCPMC9906907
OpenAlexW4319335776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.